Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say

(CNN)A booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — against Covid-19 in a Phase 3 trial, the companies announced on Thursday. They noted that …
Read More

Jacqueline Howard CNN